당뇨병신경병과 항암제유발신경병의 진단 척도

키워드

참고문헌 (34)

1. Gewandter JS, "Content validity of symptom-based measures for diabetic, chemotherapy, and HIV peripheral neuropathy", Muscle Nerve, 55, pp.366~372 (2017)
2. Kim SS, "Prevalence and clinical implications of painful diabetic peripheral neuropathy in type 2 diabetes: results from a nationwide hospital-based study of diabetic neuropathy in Korea", Diabetes Res Clin Pract, 103, pp.522~529 (2014)
3. Oh J, "Clinical scales for diabetic neuropathy", J Korean Neurol Assoc, 23, pp.34~46 (2005)
4. Feldman EL, "A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy", Diabetes Care, 17, pp.1281~1289 (1994)
5. Bax G, "Reproducibility of Michigan neuropathy screening instrument (MNSI). A comparison with tests using the vibratory and thermal perception thresholds", Diabetes Care, 19, pp.904~905 (1996)
6. Herman WH, "Use of the Michigan neuropathy screening instrument as a measure of distal symmetrical peripheral neuropathy in type 1 diabetes:results from the diabetes control and complications trial", epidemiology of diabetes interventions and complications, 2012, pp.29, 937~944
7. Fateh HR, "Correlation of Michigan neuropathy screening instrument, United Kingdom screening test and electrodiagnosis for early detection of diabetic peripheral neuropathy", J Diabetes Metab Disord, 15, pp.8~ (2015)
8. Moghtaderi A, "Validation of Michigan neuropathy screening instrument for diabetic peripheral neuropathy", Clin Neurol Neurosurg, 108, pp.477~481 (2006)
9. Bril V, "Validation of the Toronto clinical scoring system for diabetic polyneuropathy", Diabetes Care, 25, pp.2048~2052 (2002)
10. Abraham A, "Toronto clinical neuropathy score is valid for a wide spectrum of polyneuropathies", Eur J Neurol, 25, pp.484~490 (2017)
11. Bril V, "Reliability and validity of the modified Toronto clinical neuropathy score in diabetic sensorimotor polyneuropathy", Diabet Med, 26, pp.240~246 (2009)
12. Zilliox LA, "Clinical neuropathy scales in neuropathy associated with impaired glucose tolerance", J Diabetes Complications, 29, pp.372~377 (2015)
13. Dyck PJ, "Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester diabetic neuropathy study cohort", Neurology, 49, pp.229~239 (1997)
14. Dyck PJ SE, "Risk factors for severity of diabetic polyneuropathy: intensive longitudinal assessment of the Rochester diabetic neuropathy study cohort", Diabetes Care, 22, pp.1479~1486 (1999)
15. Coelho T, "Clinical measures in transthyretin familial amyloid polyneuropathy", Muscle Nerve, 55, pp.323~332 (2016)
16. Singleton JR, "The Utah early neuropathy scale: a sensitive clinical scale for early sensory predominant neuropathy", J Peripher Nerv Syst, 13, pp.218~227 (2008)
17. Fernández-Torres R, "Clinician assessment tools for patients with diabetic foot disease: a systematic review", J Clin Med, 9, pp.1487~ (2020)
18. Vinik EJ, "The development and validation of the Norfolk QOL-DN, a new measure of patients' perception of the effects of diabetes and diabetic neuropathy", Diabetes Technol Ther, 7, pp.497~508 (2005)
19. Vinik EJ, "Norfolk QOL-DN: validation of a patient reported outcome measure in transthyretin familial amyloid polyneuropathy", J Peripher Nerv Syst, 19, pp.104~114 (2014)
20. Obici L, "Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis", Amyloid, 27, pp.153~162 (2020)
21. McCrary JM, "Optimizing clinical screening for chemotherapy-induced peripheral neuropathy", J Pain Symptom Manage, 58, pp.1023~1032 (2019)
22. Gewandter JS, "Trial designs for chemotherapy-induced peripheral neuropathy prevention: ACTTION recommendations", Neurology, 91, pp.403~413 (2018)
23. Cavaletti G, "Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity", J Peripher Nerv Syst, 24, pp.111~119 (2019)
24. Hausheer FH, "Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy", Semin Oncol, 33, pp.15~49 (2006)
25. Shimozuma K, "Feasibility and validity of the patient neurotoxicity questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02", Support Care Cancer, 17, pp.1483~1491 (2009)
26. Le-Rademacher J, "Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel", carboplatin-induced peripheral neuropathy in NCCTG, Support Care Cancer, pp.2017, 25[DOI]
27. Postma TJ, "The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20", Eur J Cancer, 41, pp.1135~1139 (2005)
28. Kieffer JM, "Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20)", Qual Life Res, 26, pp.2999~3010 (2017)
29. Cella D, "Measuring the side effects of taxane therapy in oncology: the functional assesment of cancer therapy-taxane (FACT-taxane)", Cancer, 98, pp.822~831 (2003)
30. Cavaletti G, "Grading of chemotherapy-induced peripheral neurotoxicity using the total neuropathy scale", Neurology, 61, pp.1297~1300 (2003)
31. Cavaletti G, "The total neuropathy score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the national cancer institute-common toxicity scale", J Peripher Nerv Syst, 12, pp.210~215 (2007)
32. Cavaletti G, "Multi-center assessment of the total neuropathy score for chemotherapy-induced peripheral neurotoxicity", J Peripher Nerv Syst, 11, pp.135~141 (2006)
33. 김선영, "유방암 환자에게 항암화학요법 후 발생하는말초신경병에서 Total Neuropathy Score-Reduced와여러 전기생리학적검사 소견들과의 연관성", 대한신경과학회지, 37(1), pp.30~37 (2019), 대한신경과학회[DOI]
34. Perez C, "Prevalence of pain and relative diagnostic performance of screening tools for neuropathic pain in cancer patients: a cross-sectional study", Eur J Pain, 19, pp.752~761 (2015)

관련 논문AI추천